Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Mirabegron, Tamsulosin and Solifenacin in Relieving Double-J Stent Related Symptoms
NCT07447518Phase 1Completed
- Sponsor
- Kafrelsheikh University
- Start
- Sep 2022
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised trial of tadalafil, silodosin, solifenacin and mirabegron in lower urinary tract symptoms (LUTS) (5 arms), sponsored by Kafrelsheikh University. Primary endpoint: Double-J related symptoms at 6 weeks. Started Sep 2022; status: completed.
02
Drugs
tadalafilsilodosinsolifenacinmirabegron
03
Conditions
lower urinary tract symptoms (LUTS)
Beyond the preview
Go deeper on NCT07447518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07447518.